FindTrial
Sign In

ET-743 3 HOUR INFUSION EVERY 3 WEEKS, COMPASSIVE USE

ET-743 3 HOUR INFUSION EVERY 3 WEEKS, COMPASSIVE USE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-026-01
Enrollment
Unknown
Registered
2001-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

ET-743 Type of group
ET-743 should be administered at a dose of 1500 ug / m2 to 3 hours of intravenous infusion, repeated every three weeks. The drug must be administered through a central venous catheter or a peripheral tube without the use of an internal filter.

Sponsors

INSTITUTO DE ENFERMEDADES NEOPLASICAS,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Neutrophil count .1.5x10 9 / L Platelet count .I00x10 9 / L Creatinine clearance> 30 mL / min Serum bilirubin: ULN (normal upper limit and total alkaline phosphatase ... LSN If the total alkaline phosphatase> ULN, liver alkaline phosphatase fraction and 5 ´- Nucleotidase should be ^ NSL AST, ALT 25 g / L.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Outcome name:Tumor measurement, physical examination Measure:Efficacy Timepoints:Before therapy and at the end of the study—

Secondary

MeasureTime frame
Outcome name:Resgistry of adverse events Measure:Safety and Tolerability Timepoints:When the event appears—

Outcome results

None listed

Source: REPEC (via WHO ICTRP)